Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;5(8):e2228669.
doi: 10.1001/jamanetworkopen.2022.28669.

Time With Glucose Level in Target Range Among Children and Adolescents With Type 1 Diabetes After a Software Update to a Closed-Loop Glucose Control System

Marco Marigliano  1 , Andrea E Scaramuzza  2 , Riccardo Bonfanti  3 , Ivana Rabbone  4 , Riccardo Schiaffini  5 , Sonia Toni  6 , Valentino Cherubini  7 ; Virtual Educational Camp (vEC) Study Group
Collaborators, Affiliations

Time With Glucose Level in Target Range Among Children and Adolescents With Type 1 Diabetes After a Software Update to a Closed-Loop Glucose Control System

Marco Marigliano et al. JAMA Netw Open. .

Abstract

This cohort study analyzes changes to the time with glucose level in target range among children and adolescents with type 1 diabetes after a software update to a closed-loop glucose control system.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Marigliano reported receiving personal fees from Abbott; serving on the advisory board for Medtronic and Movi; receiving support for attending meetings from Movi; and has served on the speakers bureau for Abbott and Roche outside the submitted work. Dr Scaramuzza reported receiving personal fees from Sanofi and Abbott; serving on the advisory board for and receiving support for attending meetings from Movi; and receiving nonfinancial support from Medtronic outside the submitted work. Dr Bonfanti reported serving on the advisory board for Novo Nordisk, Eli Lilly, Sanofi Aventis, Abbott, Medtronic, Movi, Roche, and Ypsomed; receiving support for attending a meeting from Movi; and serving on the speakers bureau for Eli Lilly, Abbott, and Sanofi Aventis. Dr Rabbone reported serving on the advisory board for Sanofi Aventis and Movi; and serving on the speakers bureau for Aboca, Abbott, Sanofi Aventis, and Eli Lilly. Dr Schiaffini reported serving on the speakers bureau for Abbott and Lilly; receiving support for attending meetings from Medtronic and Movi; and serving on advisory boards for Abbott and Sanofi. Dr Toni reported serving on the speakers bureau for Eli Lilly, Abbott, and Sanofi Aventis; and serving on the advisory board for Movi. Dr Cherubini reported serving on the advisory board for Insulet and Eli Lilly; and his institution has received research support from AstraZeneca, Eli Lilly, and Dompè. No other disclosures were reported.

Figures

Figure.
Figure.. Early Time in Range Using the Upgraded Closed-Loop System
Percentage of time in range 1, 2, and 3 weeks before and after updating to upgraded closed-loop system and participating in a virtual educational camp. The horizontal line in each box indicates the median, the boxes indicate the IQRs, the vertical lines indicate minimum and maximum data values (excluding the outliers), and the circles indicate the outliers.
See this image and copyright information in PMC

References

    1. Battelino T, Danne T, Bergenstal RM, et al. . Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028 - DOI - PMC - PubMed
    1. Messer LH, Berget C, Pyle L, et al. . Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. Diabetes Technol Ther. 2021;23(12):837-843. doi:10.1089/dia.2021.0165 - DOI - PMC - PubMed
    1. Cherubini V, Bonfanti R, Casertano A, et al. . Time in range in children with type 1 diabetes using treatment strategies based on nonautomated insulin delivery systems in the real world. Diabetes Technol Ther. 2020;22(7):509-515. doi:10.1089/dia.2020.0031 - DOI - PubMed
    1. Saiyed M, Hasnani D, Alonso GT, et al. ; SWEET study group . Worldwide differences in childhood type 1 diabetes: the SWEET experience. Pediatr Diabetes. 2021;22(2):207-214. doi:10.1111/pedi.13137 - DOI - PubMed
    1. Cherubini V, Rabbone I, Berioli MG, et al. ; vEC Study Group . Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: a prospective, multicentre, real-life study. Diabetes Obes Metab. 2021;23(11):2484-2491. doi:10.1111/dom.14491 - DOI - PubMed